Lung cancer trials in Japan

In Japan 135 Also abroad 2747

135 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
SMP-3124LP in Adults With Advanced Solid Tumors
Where
Kashiwa-shi, Kyoto
Age
18 years and over
People
120 worldwide
Run by
Sumitomo Pharma America, Inc.
See details and how to joinNCT06526819
Phase 2Taking people
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Where
Bunkyō City, Fukuyama-shi, Kobe, Kurume-shi, Kyoto, Osaka, Sakaishi, Shinjuku-ku, Wakayama, Yokohama
Age
18 years and over
People
278 worldwide
Run by
AstraZeneca
See details and how to joinNCT07098338 · EU 2025-524843-11-00
Phase 3Taking people
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Where
Ageo, Bunkyō City, Chūōku, Fukuoka, Hidaka, Himeji, Iwakuni, Kobe, Kurume, Matsusaka, Matsuyama, Miyagi, Nagoya, Niigata, Okayama, Osaka, Saitama, Sakai, Shibukawa, Ube, Yokohama
Age
18 years and over
People
621 worldwide
Run by
BioNTech SE
See details and how to joinNCT06712355 · EU 2024-515765-34-00
Phase 1/2Taking people
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Where
Chūōku, Hidaka-shi, Kashiwa, Kōtoku, Kurume-shi, Sunto-gun
Age
18 years and over
People
460 worldwide
Run by
AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01
Phase 1/2Taking people
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Where
Kanagawa, Kyoto, Tokyo
Age
18 years and over
People
554 worldwide
Run by
Institut de Recherches Internationales Servier
See details and how to joinNCT05786924 · EU 2025-523474-16-00
Phase 3Taking people
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Where
Akashi, Fukuoka, Hidaka-shi, Hirakata, Hiroshima, Kashiwa-shi, Kobe, Koto, Kurume-shi, Nagasaki, Nagoya, Okayama, Osaka, Osakasayama-Shi, Sapporo, Sendai, Shinjuku-ku, Sunto-gun, Tokyo, Yamagata, Yokohama
Age
18 years and over
People
360 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT07128199 · EU 2025-521775-31-00
Phase 1Taking people
A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors
Where
Kyoto
Age
18 years and over
People
66 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07801508
Phase 2Not yet taking people in Japan
A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)
Where
Kitakyushu, Ōsaka-sayama, Yokohama
Age
18 years and over
People
80 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07871214
Phase 2Taking people
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
Where
Chūō, Hirakata, Kita, Kotoku, Nagoya, Osaka
Age
18 years and over
People
40 worldwide
Run by
Pfizer
See details and how to joinNCT07476287 · EU 2025-524686-24-00
Phase 1/2Taking people
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Where
Chūōku, Kashiwa
Age
18 years and over
People
120 worldwide
Run by
AstraZeneca
See details and how to joinNCT07115043
Phase 3Taking people
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Where
Asahikawa, Beppu, Bunkyo-ku, Bunkyo Ku, Chiba, Chuo Ku, Fukuoka, Higashiibaraki-gun, Hirakata-shi, Kanazawa, Kiyose, Kobe, Kochi, Kurume, Kyoto, Matsuyama, Nagoya, Nankoku, Niigata, Okayama, Ōmura, Osaka, Otashi, Sapporo, Sendai, Shinjyuku-ku, Suita, Tsu, Ube
Age
18 years and over
People
1,410 worldwide
Run by
Pfizer
See details and how to joinNCT07222566 · EU 2025-523461-17-01
Phase 2/3Taking people
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
Where
Hirakata, Kotoku, Nagaizumi-chō
Age
18 years and over
People
550 worldwide
Run by
Pfizer
See details and how to joinNCT07226999 · EU 2025-523522-41-00
Phase 1/2Taking people
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Where
Bunkyo-ku, Bunkyo Ku, Hirakata, Kashiwa, Nagaizumi-chō, Sendai
Age
18 years and over
People
162 worldwide
Run by
Pfizer
See details and how to joinNCT07227298 · EU 2025-523526-40-00
Phase 2Taking people
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
Where
Chuo Ku, Fukuoka, Kashiwa-shi, Koto-Ku, Nagoya, Niigata, Okayama, Sayama, Sendai, Sunto-gun
Age
18 years and over
People
220 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT05967689
Phase 1/2Taking people
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Where
Hirakata, Kashiwa, Koto, Nagoya
Age
18 years and over
People
327 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06780137 · EU 2024-517926-25-00
Phase 1/2Taking people
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Where
Hidaka-shi, Kashiwa, Kōtoku, Sunto-gun, Tokyo
Age
18 years to 130 years
People
622 worldwide
Run by
AstraZeneca
See details and how to joinNCT05797168 · EU 2022-502576-23-00
Phase 2/3Taking people
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Where
Bunkyo-ku, Chuo-Ku, Niigata, Sunto-gun, Takatsuki, Yokohama
Age
18 years and over
People
854 worldwide
Run by
AbbVie
See details and how to joinNCT07005102
Phase 2/3Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Where
Chuo-Ku, Sagamihara-shi, Sapporo, Wakayama
Age
18 years and over
People
490 worldwide
Run by
AbbVie
See details and how to joinNCT07155187 · EU 2025-521124-29-00
Phase 1Taking people
A Study of ZW251 in Participants With Advanced Solid Tumors
Where
Kashiwa, Kyoto, Osaka, Tokyo
Age
18 years and over
People
140 worldwide
Run by
Zymeworks BC Inc.
See details and how to joinNCT07164313
Phase 1/2Taking people
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
Where
Himeji-shi, Hirakata-shi, Kashiwa, Kōtoku, Kumamoto, Nagaizumi-chō, Niigata, Okayama, Ōsaka-sayama, Tokushima, Toyoake-shi
Age
18 years and over
People
123 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06362252 · EU 2023-509629-36-00
Phase 3Taking people
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Where
Chikusa, Fukuoka, Nagaizumi-chō, Okayama, Osaka, Sakai, Tokyo, Wakayama, Yokohama
Age
18 years and over
People
450 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT06765109 · EU 2024-517553-26-00
Phase 3Taking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Where
Akashi, Bunkyō City, Fukuoka, Hamamatsu, Iwakuni-shi, Izumi-shi, Kashihara-shi, Kobe, Kōtoku, Kurume-shi, Kyoto, Matsuyama, Nankoku-shi, Niigata, Osaka, Sakaishi, Sayama, Sendai, Shinagawa-ku, Takarazuka-shi, Toon-Shi, Toyoake-shi, Toyonaka-shi
Age
18 years and over
People
830 worldwide
Run by
AstraZeneca
See details and how to joinNCT06868277 · EU 2024-517780-24-00
Phase 1/2Taking people
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Where
Kanagawa, Okayama, Osaka, Shizuoka, Tokyo, Wakayama
Age
12 years and over
People
359 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT05118789 · EU 2024-511793-71-00
Phase 3Taking people
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
Where
Bunkyo-ku, Fukuoka, Hidaka, Hirakata-shi, Hirosaki, Kobe, Niigata, Okayama, Osaka, Sagamihara-shi, Sakai-shi, Sapporo, Sendai, Sunto-gun, Tokyo, Toyoake
Age
18 years and over
People
531 worldwide
Run by
AbbVie
See details and how to joinNCT07365241 · EU 2025-523819-11-00
Phase 1/2Taking people
A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)
Where
Osaka
Age
18 years and over
People
184 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07602855